Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

Open access

Abstract

Emerging evidence suggests that both human stem cells and mature stromal cells can play an important role in the development and growth of human malignancies. In contrast to these tumor-promoting properties, we observed that in an in vivo model of Kaposi's sarcoma (KS), intravenously (i.v.) injected human mesenchymal stem cells (MSCs) home to sites of tumorigenesis and potently inhibit tumor growth. We further show that human MSCs can inhibit the in vitro activation of the Akt protein kinase within some but not all tumor and primary cell lines. The inhibition of Akt activity requires the MSCs to make direct cell–cell contact and can be inhibited by a neutralizing antibody against E-cadherin. We further demonstrate that in vivo, Akt activation within KS cells is potently down-regulated in areas adjacent to MSC infiltration. Finally, the in vivo tumor-suppressive effects of MSCs correlates with their ability to inhibit target cell Akt activity, and KS tumors engineered to express a constitutively activated Akt construct are no longer sensitive to i.v. MSC administration. These results suggest that in contrast to other stem cells or normal stromal cells, MSCs possess intrinsic antineoplastic properties and that this stem cell population might be of particular utility for treating those human malignancies characterized by dysregulated Akt.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20051921

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. i.v. administered human MSCs home to KS tumors in vivo. Human MSCs were labeled with both superparamagnetic iron nanoparticles and the red fluorochrome CM-Dil. Where indicated, 4 × 106 labeled MSCs were injected into the tail vein of an athymic nude mouse. On the same day, 5 × 106 KS cells were injected subcutaneously into the posterior right flank. (A) MRI imaging reveals that as early as 2 d after i.v. injection, iron-labeled MSCs can be identified within the KS tumors, as indicated by the signal void created by the iron-containing MSCs within the KS tumor (arrows). Cells are seen prominently within the body of the tumor on day 4 (arrow). By day 7 after cell injection, a minimal signal void is observed at the periphery of a tumor (arrow). (B) On day 2, MSCs are diffusely distributed within the tumor, as indicated by a low power epifluorescence image superimposed on a phase-contrast photomicrograph. (C) High power epifluorescence image of a single red CM-DiI–labeled human MSC residing within a day 4 KS tumor. Cell nuclei are stained using a blue fluorescent DAPI counterstain. (D) Multiple CM-DiI–labeled MSCs within a day 4 KS tumor surround a relatively acellular, circular necrotic area within the tumor (arrows).
Figure 1. i.v. administered human MSCs home to KS tumors in vivo. Human MSCs were labeled with both superparamagnetic iron nanoparticles and the red fluorochrome CM-Dil. Where indicated, 4 × 106 labeled MSCs were injected into the tail vein of an athymic nude mouse. On the same day, 5 × 106 KS cells were injected subcutaneously into the posterior right flank. (A) MRI imaging reveals that as early as 2 d after i.v. injection, iron-labeled MSCs can be identified within the KS tumors, as indicated by the signal void created by the iron-containing MSCs within the KS tumor (arrows). Cells are seen prominently within the body of the tumor on day 4 (arrow). By day 7 after cell injection, a minimal signal void is observed at the periphery of a tumor (arrow). (B) On day 2, MSCs are diffusely distributed within the tumor, as indicated by a low power epifluorescence image superimposed on a phase-contrast photomicrograph. (C) High power epifluorescence image of a single red CM-DiI–labeled human MSC residing within a day 4 KS tumor. Cell nuclei are stained using a blue fluorescent DAPI counterstain. (D) Multiple CM-DiI–labeled MSCs within a day 4 KS tumor surround a relatively acellular, circular necrotic area within the tumor (arrows).CC BY-NC-SA · PubMed Central
Figure 2. i.v. administered MSCs inhibit KS tumorigenesis in vivo. (A) Representative tumors on day 23 in athymic nude mice receiving no treatment (KS) or receiving a single i.v. dose of 4 × 106 MSCs (KS + MSC). (B) On day 0, 5 × 106 KS cells were injected subcutaneously into the posterior right flank of each mouse alone (white bars) or in conjunction with i.v. administration of 4 × 106 human MSCs (black bars). Tumor growth and progression were monitored by biweekly caliper assessment (*, P < 0.005 on day 29; n = 4 per group). Data shown is from one experiment that is representative of results from three similar experiments. (C) Individual tumor growth curves from mice receiving a single dose of i.v. MSCs (circles) compared with growth curves from untreated animals (squares). (D) Similar design as in B except that animals received KS cells alone (white bars) or, on day 0, the simultaneous i.v. delivery of 4 × 106 HUVECs (black bars; P value is NS at day 26; n = 6 for each group). (E) Reduction in tumor volume for animals receiving multiple doses (+ + +) of 4 × 106 MSCs i.v. on days 0, 3, and 10 versus a single dose (+) of i.v. MSCs on day 0 (*, P < 0.005; n = 6 per group; single dose of MSCs vs. untreated animals; **, P < 0.001; n = 6 per group; single dose of MSC treatment vs. multiple dosages of MSC treatment). In contrast, animals receiving multiple doses of 4 × 106 HUVECS i.v. on days 0, 3, and 10 were indistinguishable from animals receiving KS cells alone. Data is expressed as the percentage of day 23 tumor volume with animals that received KS cells alone set at 100%. (F) Mean tumor volume in animals with preexisting tumors. All animals had palpable, well-established tumors before the administration of the first dosage of MSCs and were randomized to receive saline infusion or multiple doses of 4 × 106 MSCs i.v. on days 7, 13, and 17 (*, P < 0.05; n = 6 in the treated group; n = 4 in the untreated group). Error bars represent SEM.
Figure 2. i.v. administered MSCs inhibit KS tumorigenesis in vivo. (A) Representative tumors on day 23 in athymic nude mice receiving no treatment (KS) or receiving a single i.v. dose of 4 × 106 MSCs (KS + MSC). (B) On day 0, 5 × 106 KS cells were injected subcutaneously into the posterior right flank of each mouse alone (white bars) or in conjunction with i.v. administration of 4 × 106 human MSCs (black bars). Tumor growth and progression were monitored by biweekly caliper assessment (*, P < 0.005 on day 29; n = 4 per group). Data shown is from one experiment that is representative of results from three similar experiments. (C) Individual tumor growth curves from mice receiving a single dose of i.v. MSCs (circles) compared with growth curves from untreated animals (squares). (D) Similar design as in B except that animals received KS cells alone (white bars) or, on day 0, the simultaneous i.v. delivery of 4 × 106 HUVECs (black bars; P value is NS at day 26; n = 6 for each group). (E) Reduction in tumor volume for animals receiving multiple doses (+ + +) of 4 × 106 MSCs i.v. on days 0, 3, and 10 versus a single dose (+) of i.v. MSCs on day 0 (*, P < 0.005; n = 6 per group; single dose of MSCs vs. untreated animals; **, P < 0.001; n = 6 per group; single dose of MSC treatment vs. multiple dosages of MSC treatment). In contrast, animals receiving multiple doses of 4 × 106 HUVECS i.v. on days 0, 3, and 10 were indistinguishable from animals receiving KS cells alone. Data is expressed as the percentage of day 23 tumor volume with animals that received KS cells alone set at 100%. (F) Mean tumor volume in animals with preexisting tumors. All animals had palpable, well-established tumors before the administration of the first dosage of MSCs and were randomized to receive saline infusion or multiple doses of 4 × 106 MSCs i.v. on days 7, 13, and 17 (*, P < 0.05; n = 6 in the treated group; n = 4 in the untreated group). Error bars represent SEM.CC BY-NC-SA · PubMed Central
Figure 3. MSCs induce a contact-dependent inhibition of Akt activation. (A) The proliferation of KS cells is not affected by direct coculture with MSCs in full growth media. Various ratios of KS cells to MSCs are shown. (B) Change in cell number over 48 h of KS cells grown in the presence or absence of MSCs and cultured with either 2 g/liter (+) or 1 g/liter (−) glucose. KS cell growth was assessed with MSCs in a coculture format as well as in a transwell format, which prevented KS–MSC cell contact. *, P < 0.005. (C) KS cells were cocultured with MSCs for 18 h in a 1:10 (MSC/KS cell) ratio. Flow cytometric forward scatter and side scatter analysis of KS cell–MSC cocultures demonstrating the separation of viable, larger KS cells from human MSCs. Cell surface staining for Stro-1, a marker present on most human MSCs but not on KS cells, was used to further gate out MSCs (not depicted). (D) Levels of phosphorylated Akt (Ser473) in KS cells directly cocultured with MSCs (KS + MSC) were reduced compared with levels of phosphorylated Akt in KS cells alone (KS). (E) Total Akt levels within KS cells are not affected by coculture with MSCs. (F) No difference in phosphorylated Akt levels were seen in KS cells cocultured with MSCs but separated by a transwell (KS + MSC) compared with KS cells alone (KS). (G) Levels of phosphorylated ERK1 and 2 (Thr202 and Tyr204 combined) were not significantly affected by direct coculture with MSCs (KS + MSC) compared with KS cells alone. (H) KS cells were directly cocultured with MSCs for 18 h in a 1:10 (MSC/KS cell) ratio in the presence of a blocking antibody against E-cadherin. The inhibitory effects of MSCs on Akt phosphorylation in KS cells are markedly reduced in the presence of a neutralizing antibody against E-cadherin (compare with D). All of the aforementioned results are representative of at least three similar experiments. Error bars represent SEM.
Figure 3. MSCs induce a contact-dependent inhibition of Akt activation. (A) The proliferation of KS cells is not affected by direct coculture with MSCs in full growth media. Various ratios of KS cells to MSCs are shown. (B) Change in cell number over 48 h of KS cells grown in the presence or absence of MSCs and cultured with either 2 g/liter (+) or 1 g/liter (−) glucose. KS cell growth was assessed with MSCs in a coculture format as well as in a transwell format, which prevented KS–MSC cell contact. *, P < 0.005. (C) KS cells were cocultured with MSCs for 18 h in a 1:10 (MSC/KS cell) ratio. Flow cytometric forward scatter and side scatter analysis of KS cell–MSC cocultures demonstrating the separation of viable, larger KS cells from human MSCs. Cell surface staining for Stro-1, a marker present on most human MSCs but not on KS cells, was used to further gate out MSCs (not depicted). (D) Levels of phosphorylated Akt (Ser473) in KS cells directly cocultured with MSCs (KS + MSC) were reduced compared with levels of phosphorylated Akt in KS cells alone (KS). (E) Total Akt levels within KS cells are not affected by coculture with MSCs. (F) No difference in phosphorylated Akt levels were seen in KS cells cocultured with MSCs but separated by a transwell (KS + MSC) compared with KS cells alone (KS). (G) Levels of phosphorylated ERK1 and 2 (Thr202 and Tyr204 combined) were not significantly affected by direct coculture with MSCs (KS + MSC) compared with KS cells alone. (H) KS cells were directly cocultured with MSCs for 18 h in a 1:10 (MSC/KS cell) ratio in the presence of a blocking antibody against E-cadherin. The inhibitory effects of MSCs on Akt phosphorylation in KS cells are markedly reduced in the presence of a neutralizing antibody against E-cadherin (compare with D). All of the aforementioned results are representative of at least three similar experiments. Error bars represent SEM.CC BY-NC-SA · PubMed Central
Figure 4. Akt activation within cardiac myocytes and mature endothelial cells but not prostate tumor cells is inhibited by coculture with MSCs. Neonatal cardiac myocytes (CM), HUVECs, or PC-3 cells were cocultured with human MSCs at a ratio of 1:10 (MSC/target cell). 18 h after coculture, phospho-Akt levels within cardiac myocytes, HUVECs, or PC-3 cells were assessed by flow cytometry and compared with phospho-Akt levels with cardiac myocytes, HUVECs, or PC-3 cells cultured alone. (A) In MSC/HUVEC cocultures, HUVECs were repurified using an antibody against human CD31 (left). Levels of phosphorylated Akt (Ser473) in HUVECs directly cocultured with MSCs (HUVEC + MSC) are decreased compared with HUVECs cultured alone (middle). Total Akt levels in HUVECS are unchanged in the presence of MSCs compared with HUVECs cultured alone (right). (B) In MSC/cardiac myocyte cocultures, MSCs were gated out using an antibody against human CD44, which reacts with human MSCs but not mouse neonatal cardiac myocytes (left). Levels of phosphorylated Akt (Ser473) in cardiac myocytes directly cocultured with MSCs (CM + MSC) are decreased compared with cardiac myocytes cultured alone (CM; middle). Total Akt levels in neonatal cardiac myocytes are unchanged in the presence of MSCs compared with cardiac myocytes cultured alone (right). (C) MSCs were cocultured with HUVECs for 18 h in a 1:10 (MSC/HUVEC) cell ratio in the presence of a blocking antibody against E-cadherin or an IgG control antibody. The inhibitory effects of MSCs on Akt phosphorylation in KS cells seen in the presence of control IgG antibody (left) are abrogated in the presence of a neutralizing antibody against E-cadherin (right). (D) PC-3 cells were cocultured with MSCs for 18 h in a 1:10 (MSC/PC-3) cell ratio. Cell surface staining for prostate cell surface antigen was used to repurify PC-3 cells from MSCs after coculture (not depicted). Levels of phosphorylated Akt (Ser473) in PC-3 cells directly cocultured with MSCs (PC-3 + MSC) were unchanged compared with levels of phosphorylated Akt in PC-3 cells alone (PC-3). In all of the aforementioned experiments, results shown are representative of at least three similar experiments.
Figure 4. Akt activation within cardiac myocytes and mature endothelial cells but not prostate tumor cells is inhibited by coculture with MSCs. Neonatal cardiac myocytes (CM), HUVECs, or PC-3 cells were cocultured with human MSCs at a ratio of 1:10 (MSC/target cell). 18 h after coculture, phospho-Akt levels within cardiac myocytes, HUVECs, or PC-3 cells were assessed by flow cytometry and compared with phospho-Akt levels with cardiac myocytes, HUVECs, or PC-3 cells cultured alone. (A) In MSC/HUVEC cocultures, HUVECs were repurified using an antibody against human CD31 (left). Levels of phosphorylated Akt (Ser473) in HUVECs directly cocultured with MSCs (HUVEC + MSC) are decreased compared with HUVECs cultured alone (middle). Total Akt levels in HUVECS are unchanged in the presence of MSCs compared with HUVECs cultured alone (right). (B) In MSC/cardiac myocyte cocultures, MSCs were gated out using an antibody against human CD44, which reacts with human MSCs but not mouse neonatal cardiac myocytes (left). Levels of phosphorylated Akt (Ser473) in cardiac myocytes directly cocultured with MSCs (CM + MSC) are decreased compared with cardiac myocytes cultured alone (CM; middle). Total Akt levels in neonatal cardiac myocytes are unchanged in the presence of MSCs compared with cardiac myocytes cultured alone (right). (C) MSCs were cocultured with HUVECs for 18 h in a 1:10 (MSC/HUVEC) cell ratio in the presence of a blocking antibody against E-cadherin or an IgG control antibody. The inhibitory effects of MSCs on Akt phosphorylation in KS cells seen in the presence of control IgG antibody (left) are abrogated in the presence of a neutralizing antibody against E-cadherin (right). (D) PC-3 cells were cocultured with MSCs for 18 h in a 1:10 (MSC/PC-3) cell ratio. Cell surface staining for prostate cell surface antigen was used to repurify PC-3 cells from MSCs after coculture (not depicted). Levels of phosphorylated Akt (Ser473) in PC-3 cells directly cocultured with MSCs (PC-3 + MSC) were unchanged compared with levels of phosphorylated Akt in PC-3 cells alone (PC-3). In all of the aforementioned experiments, results shown are representative of at least three similar experiments.CC BY-NC-SA · PubMed Central
Figure 5. In vivo antitumorigenic effects of MSCs depend on the inactivation of Akt in target tumor cells. (A) Western blot analysis of lysates from four separate tumors harvested on day 2 demonstrates a reduction of phosphorylated Akt (Ser473) in MSC-treated animals. Total Akt levels within tumor lysates are unaffected by i.v. MSC injection. (B) Confocal fluorescence microscopy reveals that in areas surrounding MSCs (red CM-Dil–labeled cell, right), there is diminished phospho-Akt staining (green) compared with an area in the same KS tumor (left) that lacks incorporated MSCs. Cell nuclei are indicated with blue fluorescent DAPI nuclear counterstain. (C) Representative images of day 7 tumors stained with hematoxylin and eosin revealing that tumors from animals receiving i.v. MSCs (right) have more pronounced areas of central necrosis (arrows) compared with tumors from animals receiving no cells (left). (D) Quantitative blinded morphometry of multiple sections in KS tumors demonstrate a greater than twofold increase in the area of necrosis within the tumors in those animals receiving MSCs (KS + MSC) compared with tumors from untreated animals (KS). *, P < 0.01; n = 5 mice for each group, with at least five random sections per tumor analyzed. (E) On day 0, 5 × 106 PC-3 cells were injected subcutaneously into the posterior right flank of each mouse alone (white bars) or in conjunction with i.v. administration of 4 × 106 human MSCs (black bars). i.v. MSC treatment was repeated on days 3 and 10. Tumor growth and progression were monitored by biweekly caliper assessment (P value is NS on day 31; n = 5 per group). (F) On day 0, 5 × 106 KS/vector or KS/myrAkt cells were injected subcutaneously into the posterior right flank of each mouse alone or in conjunction with i.v. administration of 4 × 106 human MSCs. Data are expressed as the percentage of day 23 tumor volume compared with animals that received tumors derived from KS/vector cells alone (n = 4 animals for each group). Error bars represent SEM.
Figure 5. In vivo antitumorigenic effects of MSCs depend on the inactivation of Akt in target tumor cells. (A) Western blot analysis of lysates from four separate tumors harvested on day 2 demonstrates a reduction of phosphorylated Akt (Ser473) in MSC-treated animals. Total Akt levels within tumor lysates are unaffected by i.v. MSC injection. (B) Confocal fluorescence microscopy reveals that in areas surrounding MSCs (red CM-Dil–labeled cell, right), there is diminished phospho-Akt staining (green) compared with an area in the same KS tumor (left) that lacks incorporated MSCs. Cell nuclei are indicated with blue fluorescent DAPI nuclear counterstain. (C) Representative images of day 7 tumors stained with hematoxylin and eosin revealing that tumors from animals receiving i.v. MSCs (right) have more pronounced areas of central necrosis (arrows) compared with tumors from animals receiving no cells (left). (D) Quantitative blinded morphometry of multiple sections in KS tumors demonstrate a greater than twofold increase in the area of necrosis within the tumors in those animals receiving MSCs (KS + MSC) compared with tumors from untreated animals (KS). *, P < 0.01; n = 5 mice for each group, with at least five random sections per tumor analyzed. (E) On day 0, 5 × 106 PC-3 cells were injected subcutaneously into the posterior right flank of each mouse alone (white bars) or in conjunction with i.v. administration of 4 × 106 human MSCs (black bars). i.v. MSC treatment was repeated on days 3 and 10. Tumor growth and progression were monitored by biweekly caliper assessment (P value is NS on day 31; n = 5 per group). (F) On day 0, 5 × 106 KS/vector or KS/myrAkt cells were injected subcutaneously into the posterior right flank of each mouse alone or in conjunction with i.v. administration of 4 × 106 human MSCs. Data are expressed as the percentage of day 23 tumor volume compared with animals that received tumors derived from KS/vector cells alone (n = 4 animals for each group). Error bars represent SEM.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 8

  1. 2004, Panminerva Med., 46, 61
  2. 2000, Cancer Res., 60, 1254
  3. 1999, Cancer Res., 59, 5002
  4. 2004, Blood., 105, 1815
  5. 2004, Blood., 104, 1217
  6. 1993, Cancer Biol., 4, 231
  7. 2003, Cancer Cell Int., 3, 17
  8. 2003, Cancer Res., 63, 5821

Cited by

See all 747

Metadata

Authors
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., Zhang, J., Raffeld, M., Rogers, T. B., Stetler-Stevenson, W., Frank, J. A., Reitz, M., & Finkel, T.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Maryland Biotechnology Institute (US)
  • National Institutes of Health (US)
  • Flow Cytometry Core Facility (CH)
  • 1Laboratory of Molecular Biology, Cardiovascular Branch,
  • National Heart, Lung, and Blood Institute (US)
  • University of Maryland, Baltimore (US)
  • National Cancer Institute (UA)
  • 4National Cancer Institute; and
Venue
The Journal of Experimental Medicine
Published
2006-04-24
Volume
203
Issue
5
Pages
1235-1247
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2163234891
Cited by
747
References
60
Citations by year
2026: 6 · 2025: 16 · 2024: 20 · 2023: 31 · 2022: 25 · 2021: 34 · 2020: 37 · 2019: 41 · 2018: 38 · 2017: 28 · 2016: 53 · 2015: 56 · 2014: 38 · 2013: 79 · 2012: 51
FWCI
14.63
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • National Cancer Institute (1R01 CA09905-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
mesenchymal stem cells, Kaposi's sarcoma, anticancer activity, Akt signaling, E-cadherin, cell-cell contact, tumor stroma, stem cell homing, tumor suppression, stem cell therapy
MeSH terms
Animals, Disease Models, Animal, Enzyme Activation, Male, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Sarcoma, Kaposi, Transplantation, Heterologous, Tumor Cells, Cultured, Stromal Cells, Graft vs Tumor Effect, Mesenchymal Stem Cell Transplantation, Oncogene Protein v-akt, Mice, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. https://app.cochat.ai/papers/10.1084/jem.20051921
The paper
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., Zhang, J., Raffeld, M., Rogers, T. B., Stetler-Stevenson, W., Frank, J. A., Reitz, M., & Finkel, T. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20051921

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.